Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Metabolite Identification and Biotransformation

Our dedicated Biotransformation team includes many highly skilled scientists with diverse skill sets. They have a wealth of industrial experience in drug discovery and development spanning different therapeutic areas gained at companies such as AstraZeneca and Schering-Plough.

Our DMPK and biotransformation capabilities are supplemented by extensive experience in complementary analytical techniques, including high-resolution mass spectrometry, nuclear magnetic resonance, chemically intelligent software algorithms and mass spectrometric imaging.

This combined breadth of experience allows for a more pragmatic multi-disciplinary approach to answering critical problems around biotransformation and drug metabolism. It also brings increased confidence and clearly differentiated scientific value. Our approach focuses on answering critical questions using context-driven analytical techniques. We always aim  to provide robust submission-ready data, collaborative support and scientific leadership.

Our approach and instrumentation

At the heart of our business is the desire to solve problems and add value to the drug discovery process. Our experienced team has access to a wide range of state-of-the-art tools and technologies to complement their knowledge and expertise.

At the outset, we listen carefully to the questions our customers are looking to answer. This context-driven approach is backed up by the application of best-practice techniques to help reach clear decisions more quickly.

The precise strategy for each project will, of course, vary. We can provide fit-for-purpose levels of investigation tailored to individual problems and where a compound is in its life-cycle.

The level of detail in reports we provide will also vary, depending on the nature of the project and the necessary regulatory guidelines. It might be a metabolic soft-spot analysis, with minimal reporting. At the other end of the scale, we could be asked to supply full characterisation for a lead compound right down to agreed levels.

High-resolution time-of-flight mass spectrometry using a Waters G2-XS Q-Tof instrument is used for confident data-independent metabolite detection. This is combined with both skilled manual data interrogation and chemically intelligent  software algorithms for the characterisation of those metabolites. Together, this approach allows for maximum metabolic coverage, while also addressing key biotransformation questions, in a time-efficient manner.

 

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.